Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
(JAMA Network Open 2021) trial, this dose produced 20.5% fat mass loss and 3.6% lean mass gain in adults with T2D and obesity (BMI 28-40)
Efficacy significantly surpassed respective monotherapies
The REVOLUTION study, Diabetes Epidemiology and Management (2024) Efficacy of semaglutide in a subcutaneous and oral formulation, Frontiers in Endocrinology (2021) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial, Nature Medicine (2022) Real-world use of oral versus subcutaneous semaglutide in a cohort of Type 2 diabetic patients: which option to which patient?, Journal of Endocrinological Investigation (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, FDA.gov (2024) Dietary supplements for weight loss, National Institutes of Health Evaluation of efficacy and safety of orlistat in obese patients, Indian Journal of Endocrinology and Metabolism (2011) A systematic review of dietary supplements and alternative therapies for weight loss, Obesity (2021) Are weight loss supplements safe?, Poison Control Tainted weight loss products, FDA.gov Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
It is not intended for human or animal consumption, clinical use, diagnostic use, therapeutic use, cosmetic use, or as a food or supplement
Neither is guaranteed, but both have clear criteria that a provider can document: Document a failed Wegovy trial: You must show less than 5% weight loss after 1216 weeks at therapeutic dose
There were no significant changes in the secondary outcome variables: nutritional status, body composition, and cognitive using Friedman test
